Dietary inositols have been proposed as a natural solution to improve the metabolic disturbances associated with insulin resistance [1
]. Their beneficial effects have been attributed to their pharmacological activity as insulin sensitizers, improving insulin receptor-assciated signaling cascade. Traditionally the pharmacological action of dietary inositols was related to their incorporation into inositol phosphoglycans (IPG), complex molecules composed of one inositol, an aminosugar, and several phosphate residues. IPG species act as relevant post-receptor mediators of insulin action [3
]. These IPG-mediated actions require repeated administration of the inositols in the diet to allow the organisms to incorporate those cyclitols into the IPG structure. The importance of an external supplementation of these inositols is relevant in diabetes, where the renal clearance of inositols is enhanced because of the competition of excessive urinary glucose with inositol uptake by renal tubules [5
]. Among the several inositols studied for their potential use against insulin resistance we can cite myoinositol, D-Chiro-inositol (DCI), and D-Pinitol (DPIN, 3-0-methyl-d
-chiro-inositol), being the latter considered a potential dietary source of DCI since it can be demethylated in the acid media of the stomach. D-Pinitol is found in high concentrations in several medicinal plants (i.e., Bougainvillea spectabilis), carob pods (Ceratonia siliqua), or legumes such as soybean (Glycine max) [7
]. D-Pinitol can also be incorporated into inositolphosphoglycans (PGI), as it is the insulin’s second messenger INS-2, thus having similar effects on insulin signaling as IPG containing D-Pinitol [8
In addition to the effects derived from the dietary administration of inositols, recent studies have identified quick metabolic and hormonal responses associated with acute oral administration of these inositols, suggesting the existence of mechanisms not derived from the incorporation of inositols into IPG. From these studies, DPIN emerges as a molecule capable of improving glucose handling in oral carbohydrate load tests, both in humans and preclinical models [10
]. Detailed studies in rodents, demonstrated that the oral administration of DPIN resulted in plasma elevation of this inositol, associated with maintenance of glycemia stability, despite a clear decrease of insulin secretion [11
]. This dual effect, which might help to protect the endocrine pancreas from excessive insulin secretion, was explained based on a) enhanced ghrelin secretion that inhibits the pancreatic release of insulin and b) enhanced glucagon release that sustains glycaemia through regulation of glycolysis/neoglucogenesis processes in the liver [11
]. In addition, DPIN directly activated insulin signaling in the hypothalamus, despite the drop in plasma insulin concentrations, suggesting a direct action on post-receptor insulin signaling processes [12
]. Moreover, in vitro administration of DPIN can enhance glucose uptake in the myoblast cell line L6 [8
], acting as glucose, an effect that might also explain why hyperglycaemia is not seen despite the opposite changes in insulin and glucagon concentrations in plasma observed in the present experiment.
Overall, these effects made DPIN a molecule to be considered an active ingredient for healthy food preparations. However, except for a time frame-limited assay with either D-Pinitol [13
] or a carob fruit-derived syrup [10
], there is no information on the pharmacokinetics of DPIN in humans, and on its impact on these ghrelin-insulin-glucagon actions in healthy subjects that might confirm the activity described in rodents in preclinical assays. The present investigation addressed those questions in human healthy volunteers, as well as the potential interference that the presence of dietary glucose or fructose might exert on D-Pinitol absorption.
2. Materials and Methods
2.1. Study Design
The main aim of the study was first to investigate the oral absorption of D-Pinitol when given alone, obtaining the pharmacokinetic parameters Cmax, Tmax, and half-life after monitoring plasma concentrations of this inositol at several points after the ingestion. A dose of 15 mg/kg (equivalent to 1050 mg in a subject of 70 kg) was selected, on the basis of previous experimental findings in rodents. A pilot experiment using a low dose of 5 mg/kg was also carried out to obtain absorption data with low doses for monitoring the efficacy of absorption. A secondary aim was to analyze whether the presence of carbohydrates (glucose/fructose) might interfere with the absorption of D-Pinitol. To this end, human healthy volunteers received an oral administration of a carob pod syrup containing 50 g of total carbohydrates dose (InnoSweet ®
) containing 45.6% glucose, 47.3% fructose, 0.5% sucrose, and 3.2% D-Pinitol (50 g of syrup contains a dose of D-Pinitol of 1600 mg or 22.8 mg/kg body weight in a person weighing 70 kg). A third aim was to analyze whether the acute administration of D-Pinitol was capable of modifying glycemia and free fatty acid plasma concentrations, as well as altering glucose-modifying hormones such as insulin, glucagon, cortisol, growth hormone, and ghrelin, as it was previously described in rodents [11
]. Since D-Pinitol can be converted to D-Chiroinositol that is capable of modifying the function of the hypothalamus-hypophysis-gonadal axis, we also monitored gonadotrophins (LH and FSH) and additional pituitary hormones (Prolactin (PRL), and Thyroid-stimulating hormone (TSH)).
To achieve the aims described above, we designed a randomized trial using D-Pinitol (3-0-methyl-d
-chiro-inositol, 98% purity), or a carob pods-derived syrup (InnoSweet ®
) that was generously provided by Euronutra (https://www.euronutra.com/
(accessed on 8 July 2022), Málaga, Spain). Subjects were randomly assigned to one of the following treatments: (A) 10 subjects received pure D-Pinitol (15 mg/kg body weight) prepared in 100 mL of drinking water; (B) 6 subjects received pure D-Pinitol (5 mg/kg body weight) prepared in 100 mL of drinking water, and finally (C) 9 subjects received 50 g of carbohydrates from a natural carob pod-derived syrup (InnoSweet ®
) containing 45.6% glucose, 47.3% fructose, 0.5% sucrose and 3.2% D-Pinitol (equivalent to a dose of D-Pinitol of 1600 mg or 22.8 mg/kg body weight in a person weighing 70 kg), and diluted with 100 mL of drinking water. Sub-studies A and C were designed to analyze the pharmacokinetics of D-Pinitol in the absence (A) or presence (C) of additional carbohydrates in the solution administered, that might interfere with the absorption. Sub-studies A and B were designed to analyze the dose effect on absorption as well as the main effects on glycemia and plasma concentrations of insulin and glucagon hormones.
Concerning the sample size, we calculated it using the Gpower program, version 188.8.131.52., taking into consideration that the expected variations in plasma D-Pinitol concentrations might exceed 3-fold in between time points. Recruitment of male and female volunteers was carried out to reach the calculated sample size, as described in Table 1
and the statistics section.
In this case, 25 healthy volunteers were recruited among healthy clinical and laboratory staff of the Laboratory of Neuropsychopharmacology of the Regional University Hospital of Málaga. The inclusion criteria for all subjects were (a) age range of 18–65 years, (b) the presence of a baseline capillary blood glucose < 5.6 nmol/L (100 mg/mL) measured with a glucose oxidase method after overnight fasting, (c) the absence of obesity (BMI > 30) and the absence of a diagnosed/treated metabolic disease. Subjects were interviewed for present or past diagnosis of diabetes (Glucose > 7.8 mmol/L after a standard glucose load), hypertryglyceridemia, or hypercholesterolemia under treatment, as well as for a clinical record of past endocrine disorders including thyroid gland dysfunction or treatment with glucocorticoids. Based on the inclusion criteria, exclusion criteria were pregnancy or lactation, fasting glycemia > 5.6 mmol/L (100 mg/dL), and fasting insulinemia determined by ELISA > 25 mIU/L. diabetes or medication known to interfere with carbohydrate metabolism. Any of the women included used contraceptive medication. The main data of men and women participants can be found in Table 1
. The study was conducted under the guidelines of the Declaration of Helsinki, and the research protocol was approved by the Ethics Committee of the Regional University Hospital of Málaga, under protocol number P18-TP-5194.
2.3. Blood Sample Collection, Plasma Preparation, and Glucose Concentration Monitoring
After 12 h overnight fasting, a catheter was inserted into the antecubital vein of each subject, blood was extracted at baseline (minute 0; while still fasting), and immediately after (within 5 min) oral intake of the assigned doses of either DPIN (15 mg/kg) or the natural syrup. Next, blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 1440 min after intake. Individuals were allowed to eat 6 h after the first blood sample. All-time points were used for measuring DPIN concentrations. Time points between 0 min (basal) and 180 min post DPIN(15 mg/kg) intake were used for measuring glucose, free fatty acids, glucagon, and insulin. Time points 0, 120 and 180 min post-D-Pinitol intake were used for the analysis of prolactin, thyroid-stimulating hormones, and gonadotropins. Time points of 0, 60, and 120 min post DPIN intake were used for measuring both, growth hormone and cortisol concentrations. In the case of the DPIN dose of 5 mg/kg dose, blood was withdrawn only at 0, 60, and 120 min post-DPIN ingestion to compare with the absorption observed with higher doses. All the blood samples were collected in Vacutest tubes (Vacutest Kima S.r.l., Arzergrande, PD, Italy, cat. number: #13560), centrifuged at 2000× g for 10 min at 4 °C, and the plasma was kept at −80 °C for further biochemical analysis.
Right after the blood was extracted from the subjects, plasma was obtained by centrifugation and plasma glucose concentrations were measured with a commercially available glucometer (AccuCheck, Roche, Germany).
2.4. Quantitation of Pinitol: Liquid Chromatography-Mass Spectrometry Method
2.4.1. Mass Spectrometry Method
A quantitation method for D-Pinitol in human plasma using liquid chromatography coupled to mass spectrometry (LC-MS/MS) was validated. Analysis was carried out using an Agilent 1290 (Agilent Technologies, Santa Clara, CA, USA) liquid chromatographer and an Api4000 triple quadrupole mass spectrometer (SCIEX). Quantitation was obtained using the multiple-reaction monitoring (MRM) mode of the transitions at m/z 195.2→109.0 (quantitative) and 195.2/80.0 (qualitative) for D-Pinitol both with collision energy to 20 Ev, and m
261.1→205.1 for the internal standard (IS), see Figure 1
A,B. IS was provided by MEDINA.
Mass spectrometry conditions consisted of decluster potential (DP): 10 eV, GS1 and GS2: 45 psi, Tª: 600 °C and Ions spray: 5500 Ev. Chromatographic conditions were the following, the mobile phase (MP) consisted of 0.1% formic acid−[water:AcN] [90:10] (MP A) and 0.1% formic acid−[AcN:water] [90:10] (MP B). The gradient program was applied as follows: t = 0−0.5 min 95% MP B; t = 4.50–6.70 min 25% MP B; t = 6.80 95% MP B, t = 6.80–9:00 min 95% MP B. The flow rate was 0.3 mL/min and the run time was 9 min. The injection volume was 5 μL. The chromatographic column used was X bridge BEH amide (waters) with dimension 2.1 × 100 mm and particle size 3.5 μm. The oven column was maintained at 30 °C. The method performance was validated according to the FDA recommendations proposed in 2018 for selectivity, sensitivity, matrix effect, linearity, precision, accuracy, and recovery of plasma samples [14
2.4.2. Sample Preparation
An aliquot of 50.0 μL plasma was taken and 2% TFA plus 150 μL of cold methanol containing the internal standard was added. After vortex mixing for one minute, the samples were centrifuged for 15 min at 13,300 rpm. The temperature of the centrifuge was set at 4 °C. An aliquot of 160.0 μL of the supernatant was transferred to a vial for evaporation. The samples were reconstituted in 100 μL water/acetonitrile (80/20) and 0.1% ammonia (20%) for LCMS analysis.
2.4.3. Pharmacokinetic Study
All pharmacokinetic parameters were estimated from the mean concentration values (n
= 5–10) determined at each time point and were evaluated by noncompartmental analysis using PKSolver (Version 2.0) [15
2.5. Quantitation of Glucose and Plasma Hormone Concentrations
Glucose homeostasis-related hormones: plasma levels of hormones regulating glucose homeostasis were determined by the Enzyme-Linked ImmunoSorbent Assay (ELISA) method using commercial kits: insulin (EMD Millipore Corporation, Billerica, MA, USA, cat. number: #EZHI-14K, intra-assay coefficient of variation of 4.86; inter-assay coefficient of variation of 5.73), glucagon (Elabscience Biotechnology Inc., Wuhan, Hubei, China, cat. number: #E EL H2237, intra-assay coefficient of variation of 5.36; inter-assay coefficient of variation of 7.95) and active ghrelin (Kamiya Biomedical Company, Seattle, WA, USA, cat. number: #KT-364, intra-assay coefficient of variation of 6.62; inter-assay coefficient of variation of 25.31).
Free fatty acids plasma concentration was measured using a commercial kit (Sigma-Aldrich, Saint Louis, MO, USA, cat. number: MAK044) according to the manufacturer’s instructions. All serum samples were assayed in duplicate within one assay, and results were expressed in terms of the particular standard metabolite.
Insulin resistance was evaluated according to the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR index), calculated using the following formula: HOMA-IR = ((fasting plasma insulin [μIU/mL] × fasting blood glucose [mmol/L])/22.5). Homeostatic assessment of β-cell function index (HOMA β), was calculated using the formula: HOMA β = [(360 × fasting serum insulin in μU/mL)/(fasting blood glucose in mg/dL − 63)] [16
]. With the previously insulin and glucagon values obtained we calculated the glucagon/insulin ratio.
Plasma levels of pituitary hormones: follicle-stimulating hormone (FSH, expressed in mU/mL; intra-assay coefficient of variation of 7; inter-assay coefficient of variation of 8), human growth hormone-1 (GH, expressed in ng/mL; intra-assay coefficient of variation of 6; inter-assay coefficient of variation of 7), luteinizing hormone (LH, expressed in mU/mL; intra-assay coefficient of variation of 4; inter-assay coefficient of variation of 6), prolactin (PRL, expressed in ng/mL; intra-assay coefficient of variation of 8; inter-assay coefficient of variation of 10.4) and thyroid stimulating hormone (TSH, expressed in µU/mL; intra-assay coefficient of variation of 7; inter-assay coefficient of variation of 8.1) were determined by multiplex immunoassay system, using a commercial kit: Bio-Plex Pro™ RBM Human Hormone Panel 1 (Bio-Rad, Hercules, CA, USA, cat. number: #171AHR1CK). The plate was run on a Bio-Plex MAGPIX™ Multiplex Reader with Bio-Plex Manager™ MP Software (Luminex, Austin, TX, USA). Hormone detection limits were: 0.11 mU/mL (FSH), 0.0076 ng/mL (GH), 0.061 mU/mL (LH), 0.022 ng/mL (PRL) and 0.012 µU/mL (TSH).
Plasma cortisol levels were determined using a commercial kit (Cayman Chemical Company, Ann Arbor, MI, USA, cat. Number: 500360; intra-assay coefficient of variation of 17.6; inter-assay coefficient of variation of 18.7) according to the manufacturer’s instructions, plasma preparation was performed as recommended by the kit, and results were expressed in terms of the standards provided. Absorbances obtained after reading the plate were analyzed using a computer spreadsheet provided by the same producer, available at https://www.caymanchem.com/analysisTools/ELISA
(accessed on 22 March 2022).
2.6. Statistical Analysis
The main variables of the study were the Cmax and the area under the curve (AUC) obtained when monitoring variations of plasma D-Pinitol levels at different times after oral intake. Since plasma concentrations at the different time points selected after oral intake of D-Pinitol can display more than a 3-fold variation, we selected a restrictive size of the effect of 2. That gives a sample size of 7 subjects per group for comparing D-Pinitol levels versus time after ingestion of either D-Pinitol or Carob Syrup. Since we wanted to have a representation of men and women, we increased the numbers to 10 and 9 respectively. For the dose of 5 mg/kg, we could only recruit 6 out of the 7 subjects, so we decided to present these data as supplementary information
, but we did not perform a full analysis with this sub-study; thus, we recruited a total of 25 subjects.
Graph-Pad Prism 8.0 software (GraphPad Software, Inc., San Diego, CA, USA) was used to analyze the data. Values are represented as mean ± standard error of the mean (SEM) for each experimental group, according to the assay. The significance of differences within and between groups was evaluated by a one-way or two-way (depending on the assay) analysis of variance (ANOVA) followed by a posthoc test for multiple comparisons. A p-value ≤ 0.05 was considered to be statistically significant. (* = p < 0.05; ** = p < 0.01; *** = p < 0.001).
The present study shows the pharmacokinetic profile of D-Pinitol when given orally as a pure food ingredient alone. Data reveals that after ingestion of DPIN, it follows an extended period of absorption that lasts almost four hours, decreasing thereafter. The present experimental design includes sampling times (6 and 24 h post-DPIN ingestion) that were not evaluated in previous studies monitoring plasma DPIN concentrations after oral intake. Those studies limited the analysis of DPIN concentrations to the first 4 h post-ingestion, complicating any estimation of pharmacokinetics properties of DPIN [10
]. The present design allowed the calculation of DPIN half-life that reached five and a half hours. This long half-life value allows coverage of large postprandial and nocturnal periods, where the DPIN might exert its effects after a single administration. The maximal concentrations of DPIN (Cmax of 1392 ng/mL (7.17 μM)) observed in our experimental design, where the dose was adjusted to the weight of each subject, are in agreement with previous published using either DPIN alone (1 g of DPIN, yielding Cmax around 10 μM [13
]) and those observed after ingestion of higher doses of DPIN in a natural syrup (Cmax of 1670 ng/mL (8.6 μM) for a dose of 2.5 g of DPIN [10
]). It is important to highlight that both studies were carried out in the context of a glucose load experiment, where the presence of this monosaccharide might interfere with the absorptive processes of DPIN. This is what can be deduced from the Cmax of the study that used a 2.5 g of DPIN from a natural syrup (InnoSweet ®
), whose value did not duplicate the Cmax of our study, where doses were in the range of 0.75–1.3 gr/person, depending on the weight of the subject. The small difference in the Cmax between both studies indicates that in the presence of carbohydrates, mainly monosaccharides, DPIN absorption is reduced, probably because of the competition of glucose and fructose for the inositol transporter [18
]. We confirmed this finding in a parallel study using a natural syrup containing monosaccharides (45.6% glucose, 47.3% fructose, 0.5% saccharose, and 3.2% D-Pinitol, % weight) at a dose equivalent to 1.6 gr/subject of DPIN. While half-life was identical, Cmax was not different, reaching 1492 ng/mL, despite being the D-Pinitol dose used in the syrup (22.8 mg/kg in a person of 70 kg) 50% greater than de 15 mg/kg dose used in the study where D-Pinitol was given alone A pilot study (see Supplementary Materials
) with a dose of 5 mg/kg of DPIN indicated that the absorption was proportional to the dose administered since we did not observe an enhancement or lowering of the expected plasma concentrations of DPIN that might suggest dose-dependent changes in the efficiency of the absorption.
The second novelty of the present study is the description of the pharmacological effects of DPIN on both, glycemia and on the secretion of glucose homeostasis-related hormones in fasting healthy humans. Administration of 15 mg/kg of DPIN resulted in a pharmacological profile very similar to that found in preclinical rodent models [11
]. D-Pinitol administration resulted in a small decrease in insulinemia at 90-, 120- and 180-min post DPIN intake, without affecting glycemia. The surprising stability of glycemia despite the reduction of insulin secretion was found in preclinical studies [11
] to be mediated by the inhibition of liver pyruvate kinase, slowing glycolysis, and favoring the export of glucose to the blood circulation to sustain glycemia. Interestingly, insulin levels decreased 90, 120 and 180 min after oral intake of DPIN, and glucagon rises rapidly throughout the 3 h interval analyzed. Overall, the basal HOMA IR and HOMA β indexes resulting from these opposing pharmacological actions (Figure 4
C,D) reflect stability in glucose homeostasis despite the net reduction in insulin secretion. This pharmacological profile of effects was explained in preclinical models by two mechanisms, a) a direct inhibitory action of DPIN on insulin secretion by pancreatic β-cells through modulation of ERK1/ERK2 signaling and b) the inhibitory action on insulin secretion exerted by acylated ghrelin (active form), that was enhanced by DPIN. In the absence of experimental data on the actions of DPIN in human islets or human hepatocytes, we cannot confirm this mechanism in humans- However, we did observe the increment of acylated ghrelin (the active form of the hormone) in humans subjected 60 min after the ingestion of DPIN. Interestingly, the effects of DPIN did not include a decrease of circulating free fatty acids (FFA) (Figure S2
) consistent with direct insulin-mimetic action in the liver. Since glucagon promotes the release of free fatty acid in humans [19
], blocking de novo synthesis of FFA, we interpret that DPIN sustains the release of FFA through the actions of glucagon, whose release is enhanced by the administration of this inositol. This finding may have a very interesting therapeutic potential in non-alcoholic steatohepatitis (NASH), where DPIN consumption might reduce liver steatosis and insulin resistance/diabetes type 2. Preliminary data recently published support this view [20
]. Further studies are needed to demonstrate up to which point the actions of DPIN described in fasting humans are translated to better glucose homeostasis responses when a glucose tolerance test is performed combining oral administration of glucose and DPIN.
Regarding the effects of the 5 mg/kg dose, it is difficult to compare the changes in glucose homeostasis-associated plasma parameters (see Supplementary Materials
) between both doses of D-Pinitol. The critical time points in the higher DPIN dose were not evaluated in the lower DPIN dose. For the higher DPIN dose, glucose decreased during the first 30 min (not measured in lower DPIN dose) and insulin decreased at 90 and 180 (not measured in lower DPIN dose). Therefore, it is unknown how the lower dose would have responded at these certain time points. More research is needed to clarify which is the minimum dose required for the beneficial effects of DPIN in humans.
The fact that DPIN administration resulted in enhanced Ghrelin release, together with the well-known effects of inositol on the gonadal axis [21
], prompted us to examine the impact of this inositol on circulating levels of pituitary hormones. Surprisingly, DPIN, at the doses studied, only affected growth hormone (GH) secretion. The circulating concentrations of neither the gonadotrophins nor PRL or TSH were influenced by DPIN. The case of GH was intriguing since the rise of ghrelin, a GH secretagogue, and the drop of insulin that inhibits somatotroph release of GH (for review see [23
]), might us expect a different profile of effects. However, experimental data in animal models suggest that DPIN might exert a potent insulin-mimetic action in the hypothalamus (acting on insulin receptor signaling cascade but not through a direct effect on insulin receptors) [12
], and potentially in the somatotrophs, deregulating the hypothalamic control of GH via growth hormone release hormone (GHRH) and mimicking insulin on its direct inhibitory effect on pituitary GH secretion [24
]. Whether this stimulatory effect of DPIN on hypothalamic insulin signaling happens in humans is still unknown, but it might explain the inhibitory action on GH levels. Interestingly, cortisol, a glucocorticoid that elevates glycemia, is reduced by DPIN, a fact that might reduce the need for additional pancreas insulin. However, in the absence of data evaluating the impact of DPIN on pituitary adrenocorticotrophin hormone (ACTH) secretion, we cannot identify whether the effects of DPIN on cortisol secretion are directly exerted in the adrenal gland or through disruption of hypothalamic/pituitary control of ACTH secretion. The lack of inhibitory effect of DPIN on FSH is also a relevant finding in the context of obesity and insulin resistance since this deficit in this hormone has been linked to NASH in populational studies [26
Overall, the present study supports a protective role/preventive role derived from DPIN consumption on the endocrine pancreas, by reducing the load of insulin secretion and thus reducing one of the main factors contributing to insulin resistance. This is a novel complementary approach to the insulin-mimetic actions of D-Pinitol in the context of diabetes type 2 [27
]. In addition, it suggests a preventive role in the development of liver steatosis, through the stimulatory role of glucagon secretion. However, several limitations demand more research to fully establish this hypothetical therapeutic role for dietary DPIN. It is important to understand the pharmacokinetics after repeated administration of this inositol, to establish adaptive changes on its metabolism/clearance. It is also very important to identify if the pharmacokinetics is influenced by other dietary elements, the existence of obesity/diabetes, and the presence of age-associated factors such as menopause. In any case, the present set of data establishes a framework for exploring the utility of this dietary ingredient.
Although the data obtained in the present study might help to establish the potential use of DPIN as a dietary strategy to fight against insulin resistance and diabetes type 2, (either alone or as an active ingredient in food preparations), there are several limitations to be considered. First, the small number of subjects might affect the evaluation of certain endocrine effects, especially affecting hormones with pulsatile secretion (i.e., gonadotrophins), or circadian rhythm-affected hormones (i.e., glucocorticoids). This is especially important for women, since we did not register the menstrual cycle phase of the female volunteers, a factor that must be considered in future experimental approaches. However, we considered that the sample size chosen is consistent with the goals of the study and enough to determine the pharmacokinetics parameters of oral administration of D-Pinitol, the main goal of the present investigation. Although the number of subjects and doses is limited and should be increased in future studies, it is remarkable that the pharmacological actions of D-Pinitol on the ghrelin-insulin-glucagon endocrine network-aligned with the results obtained from previous animal studies [11
]. Another limitation is the need to increase the number of male and female subjects for having a clear power to differentiate potential sex-dimorphic responses. Finally, since D-Pinitol can be converted into D-chiroinositol by acid demethylation in the stomach, a study comparing the direct action of D-Pinitol with D-Chiroinositol has to be addressed.